Generated by Apex Intelligence. Verify key information against the sources. For information and education, not personalized investment advice. See full disclaimer

Worth noting Market event Fri, Nov 6 2 min read

Lilly strikes Hims & Hers deal to widen access to approved obesity drugs

Lilly and Hims & Hers announced an agreement on November 6, 2026, to give eligible patients access to Zepbound (tirzepatide) and Foundayo (orforglipron), both FDA-approved medicines, through the Hims & Hers online healthcare platform. Patients who receive a prescription from a licensed provider on the platform will be able to obtain the medicines without leaving it, at the same self-pay prices available to other patients.^[1]

As part of the agreement, Hims said it would not compound GLP-1 medicines like Zepbound in the future, according to related coverage. GLP-1 medicines help manage weight through effects including appetite regulation; compounding means having a pharmacy prepare its own formulations.^[2]

Connecting prescribing and medicine access on one platform can reduce the steps patients take to obtain treatment. If that leads more patients to start and continue treatment, Lilly could gain prescription sales and Hims could attract and retain more weight-management customers. The agreement creates a route to that growth; the payoff depends on patient uptake.^[1]

Giving up future GLP-1 compounding also makes Hims's weight-management offering more dependent on branded drug supply and manufacturer partnerships. Investors therefore need to weigh the demand opportunity from added treatments alongside the business effect of a narrower choice of products to offer.^[1]^[2]

Impact

Back to the market

Branded obesity-drug manufacturersOpportunity
Lilly gains a route to Hims's self-pay patients alongside Hims's pledge to forgo future GLP-1 compounding. That strengthens branded medicines' place in the platform's future offering and gives rival obesity-drug makers a broader Lilly distribution network to compete with.^[1]^[2]
Online healthcare and weight-management platformsNeutral
Hims can use access to Lilly's approved medicines to attract patients, while giving up the option of offering compounded GLP-1 drugs in the future. For competing platforms, the deal raises the importance of manufacturer relationships and a convenient treatment-access experience in winning self-pay customers.^[1]^[2]